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Abstract
About 30% of patients with Cystic Fibrosis (CF) develop CF-associated liver disease
(CFLD). Recent studies have shown that transient elastography (TE), as a method to quan-
tify liver stiffness, allows non-invasive diagnosis of CFLD in adults and children with CF.
Within this study we aimed to prospectively identify patients at risk for development of CFLD
by longitudinal analysis of liver stiffness and fibrosis scores in a 5-year follow-up. 36 pediat-
ric and 16 adult patients with initial liver stiffness below the cut-off value indicative of CFLD
(6.3 kPa) were examined by transient elastography for 4–5 years. TE, APRI-, and FIB-4-
scores were assessed and compared by Kruskal-Wallis test and receiver operating charac-
teristic (ROC)-analysis. Frequencies were compared by Chi2-test. Among the 36 patients
participating in this study, a subgroup of 9 patients developed liver stiffness >6.3 kPa after
4–5 years with an increase of ΔTE >0.38 kPa/a (the group with increasing liver stiffness was
labelled TEinc). APRI- and FIB-4 scores confirmed the rationale for grouping. The frequency
of CFLD assessed by conventional diagnosis was significantly higher in TEinc-group com-
pared to the control group (TEnorm). None of the adult CF patients matched criteria for TEinc-
group. For the first time it was shown that the non-invasive longitudinal assessment of TE
allows identification of patients with progression of CFLD in a subgroup of juvenile but not in
adult CF patients. Comparing TE to conventional fibrosis-scores underlined the strength of
the continuous assessment of liver stiffness for the exact diagnosis of progressive CFLD.
The newly described cut-off for pathologic increase of liver stiffness, ΔTEcutoff = 0.38kPa/a,
might enable to detect developing CFLD using consequent follow up TE measurements
before reaching the level of stiffness indicating established CFLD. Nevertheless, the limited
size of the analyzed cohort should encourage a prospective, multi-center, long term follow
up study to confirm the suggested cut-off for the rise in liver stiffness.
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Introduction
Cystic fibrosis (CF) is the most common multisystem autosomal recessive genetic disorder with a
high morbidity and mortality in Caucasian population with an incidence of approximately 1 of
3500 births worldwide [1]. Despite continuous improvements in the treatment of CF patients,
the disease is associated with a high annual mortality rate of 1.6% with a median age at death of
29.1 years [1]. According to the current Cystic Fibrosis Foundation Patient Registry, Cystic Fibro-
sis associated liver disease (CFLD) causes 2.5% of the overall mortality of CF patients and repre-
sents the third most common cause of death in CF patients [1]. To date, liver biopsy remains the
gold standard for the assessment of the severity of liver diseases such as fibrosis and cirrhosis [2].
However, it is an invasive and painful procedure with rare but potentially life threatening compli-
cations which is a limitation to its acceptance and repetition, especially in children. Hence, a wide
range of research has been focused on the development of non-invasive methods to diagnose the
CFLD. Several studies were able to prove that quantification of liver stiffness by transient elasto-
graphy (TE) is a novel, non-invasive method for the diagnosis of CFLD [3–6]. However, all stud-
ies evaluating TE for the non-invasive diagnosis of CFLD are retrospective and cross sectional. A
prospective longitudinal non-invasive CFLD evaluation has not been reported so far. Longitudi-
nal data of liver stiffness from patients with developing CFLD might allow to specify a cut-off for
the rise in liver stiffness. Consequently, this cut-off might be a valuable diagnostic tool to identify
developing CFLD before reaching the level of stiffness which is known for established CFLD. The
aim of this study was to define a cut-off for the rise in liver stiffness in a prospective longitudinal
cohort study. Within this study, we prospectively assessed in a 5-year follow-up whether transient
elastography allows the identification of patients at risk for the progression of liver disease. For
this purpose, patients received an annual quantification of liver stiffness by TE and the results
were compared with two well-known fibrosis scores, APRI and FIB-4. Our results show that this
approach has the potential to identify CF patients at risk of developing progression of CF liver
disease.
Materials and methods
Study subjects and design
This prospective 5-years follow-up study was performed during the period of 2009–2015. It
has been conducted according to the principles of the Declaration of Helsinki and approved
by the ethics committee of the medical faculty of the Justus-Liebig-University Giessen (35392
Giessen, Germany) with the approval No. 75/09.
All participating adult patients and the parents of the pediatric patients received, signed
and agreed with the written informed consent for the procedure for the upcoming period of
minimum five years in all cases. The treatment meets all requirements of the European and U.
S. guidelines [7].
The diagnosis of CF was an essential prerequisite for participating in this study and was
established by the sweat chloride test with application of pilocarpine and the positive gene
mutation tests with elevated immunoreactive trypsinogen (IRT) in all subjects.
In total, 173 out-patient positive cystic fibrosis (CF) patients, 85 males and 88 females, with
a median age of 13 (2–47), were treated at the Department of Internal Medicine at the Univer-
sity Hospital Giessen. The cohort was classified into patients with liver disease (CFLD) on the
one hand or without liver disease (CFnoLD) on the other hand according to the clinical guide-
line criteria published by Debray in 2011 [8]. They are defined as presenting at least two of the
following conditions for CFLD on at least two consecutive examinations spanning a one-year
period:
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• hepatomegaly with or without a splenomegaly
• two abnormal serum liver enzyme levels (ALT, AST, γ-GT> upper limit of normal)
• other ultrasound parameters of liver abnormalities than hepatomegaly such as varied echo-
genicity, increased density, nodules, rough liver margins, evidence for portal hypertension
(i.e. dilatation, splenomegaly, ascites. . .)
Patients with other diagnosed causes for chronic hepatobiliary diseases were excluded of
this study [8].
All patients underwent clinical examination at intervals of approximately once a year.
In addition, each patient received regular haematological and biochemical investigation as
well as a pulmonary function test (FEV1, VC) [9,10].
Results were computed to APRI (Aspartate Aminotransferase to Platelet Ratio = AST/
upper limit of normal AST x 100/Platelet Count (109/l) and FIB-4 (Fibrosis-4 = Age (years) x
AST (U/l) / Platelets 109/L x 3 ALT (U/l)) which are validated to detect fibrosis and predict cys-
tic fibrosis liver disease (CFLD), as described by Leung et al. [2].
Furthermore, all patients underwent a regular abdominal ultrasound examination (Philips
HD 11X E) as well as an examination with the transient elastography (TE) with FibroScan1.
Our study focuses on juvenile patients, whose valid and complete measures were conducted
over 4–5 years. Those with an already existing high liver stiffness (above the cut-off) were
excluded from this study.
Transient elastography
Assessment of liver stiffness was performed as described before [6].
Statistical analysis
After collecting the patients´ demographic and clinical characteristics of up to 5 years, IBM
SPSS Statistics 22.0 (SPSS Inc., Chicago, III) was used to summarize and perform the statistical
analysis.
Differences in the TE values, ΔTE, median TE (0–5), as well as APRI- and FIB-4-score were
assessed and compared in multiple tests using the Kruskal-Wallis-test.
The values of the liver stiffness measured with TE, APRI- and FIB-4-score are visualized in
Box- and- Whisker-Plots. Outliers (o) define the values deviating from the box at 1.5- to 3-fold
interquartile range. Significant and highly significant differences are pointed out (p0.05,
p0.001). Pearson’s Chi-square test compares and differentiates between the frequency of
CFnoLD and CFLD in the two subgroups.
The diagnostic performance and accuracy of TE, APRI, FIB-4 and ALT were assessed by
using the receiver operating characteristics (ROC)-analysis.
Results
For 60 of the 173 CF patients, including 16 adults and 44 children, follow-up data with initial
and regularly consecutive TE over 4–5 years and quantification of APRI- and FIB-4 scores
were available (Fig 1). 21 of the 44 pediatric patients were diagnosed with CFLD as defined by
clinical guidelines criteria [8] during the follow-up. Compared to children without CFLD,
those with CFLD had significantly elevated mean values of liver stiffness, serum ALT, and
APRI over the follow-up while FIB-4 was not altered: TE(noCFLD) = 4.5±0.16 kPa and TE
(CFLD) = 8.2±1.6 kPa with p<0.001, ALT(CFnoLD) = 24.7±1.6 U/l and ALT(CFLD) = 39.2
±4.7 U/l with p<0.003, APRI(CFnoLD) = 0.20±0.02 and APRI(CFLD) = 0.36±0.08 with
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Fig 1. Derivation of study cohort. TE = Transient elastography.
https://doi.org/10.1371/journal.pone.0178784.g001
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p = 0.007. The values were calculated as means of all measurements at all time points during
the follow-up. In theROC-analysis, the following diagnostic accuracies of TE, serum ALT,
APRI- and FIB-4 scores for the distinction between CFLD and CFnoLD were calculated: AUC
(TE) = 0.91±0.05 with p<0.001, AUC(ALT) = 0.76±0.08 with p = 0.003, AUC(APRI) = 0.74
±0.08 with p = 0.007, AUC(FIB-4) = 0.62±0.09 with p = 0.17. These data are consistent with
the results of previous studies [2,5,6]. Based on these results, we then aimed to analyze whether
TE or non-invasive fibrosis scores might be able to identify CF patients at risk for developing
CFLD during the course of the disease.
This prospective identification of pediatric patients at risk for the development of CFLD,
analyzing the liver stiffness and the fibrosis scores longitudinally, required the following strati-
fication (Table 1): 36 children of the 44 pediatric patients had an initial liver stiffness TE(0)
below the threshold of 6.3 kPa which has been shown to be the optimum for the distinction of
patients with and without CFLD [5].
10 (28%) out of 36 pediatric CF patients had a final stiffness above the threshold of 6.3 kPa in
the fourth and fifth year. In order to identify those patients with a continuous rise of liver stiff-
ness and final stiffness above the threshold of 6.3 kPa, the optimal cut-off for the mean increase
in TE was calculated by ROC analysis to be ΔTEcut-off = 0.38kPa/year (Fig 2A). Eventually, 9
(25%) out of 36 pediatric CF patients showed a mean increase in TE-value of>0.38kPa per year
(group labelled TEinc with ΔTEinc>0.38kPa/year). 27 pediatric CF patients (75%) exhibited a
stable stiffness value below the threshold of 0.38 kPa/year. These patients were labelled TEcon
and served as a control group for those 9 (25%) pediatric CF patients with a continuously
increasing liver stiffness (target group TEinc). Fibrosis scores APRI and FIB-4 as well as clinical
parameters specific for liver disease were assessed.
As shown in Table 1, patients with TEinc and TEcon did not differ in the baseline demo-
graphics and clinical data such as age, BMI, or the involvement of the pancreas and liver
enzyme levels. Furthermore, there was no difference in the liver stiffness and fibrosis scores at
the beginning of the study between the patients with stable liver stiffness over time and those
with exacerbation.
It is important to mention that when TEcon and TEinc patients were stratified according to
the criteria for CFLD diagnosis by Debray et al [8] and analyzed by Chi-square test, it showed
that longitudinal liver stiffness measurements with TE were able to distinguish CFnoLD and
CFLD with a high significant value of χ2 = 0.001(). As illustrated in Fig 2B, within TEcon
patients only 5 (18.5%) patients developed CFLD during the follow-up period, as diagnosed by
guideline criteria. In contrast, out of the 9 patients within the TEinc group, 8 patients (= 88.9%)
were diagnosed with CFLD according to the criteria by Debray during the follow-up. Fig 2C
and 2D demonstrate the differences in ΔTE and median TE(year 0–5) between TEcon and
TEinc. The median values of the yearly increase of liver stiffness were ΔTEinc = 0.82 kPa (0.46–
1.79) and ΔTEcon = -0.05 kPa (-0.76–0.3) with p<0.001. Similarly, the difference in median
stiffness definitely supported the distinction of the two groups: median TEcon(year 0–5) = 4.5
kPa and median TEinc(year 0–5) = 5.45 kPa, p<0.001 (Fig 2D).
In the TEinc group, the increase of liver stiffness was mostly pronounced and highly
significant (p<0.001) in the fourth and fifth year of the follow-up (Fig 3A). This increase
in liver stiffness was accompanied by an enhanced FIB-4 score with a median yearly
increase of 0.03 (0–0.09, p = 0.003) at the fourth year of the follow-up while the APRI
score increased tendentially but did not reach the level of significance (Fig 3B and 3C).
Both, APRI and FIB-4, were positively correlated with liver stiffness (rAPRI-TE = 0.78,
p<0.001 and rFIB-4-TE = 0.75, p<0.001).
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Discussion
CFLD is a relatively frequent and an early complication of CF develops in 5–10% of children
within their first decade of life. There is also a chance of 4.5% of an incidence of cirrhosis dur-
ing a median period of 5 years from the time of the diagnosis of the liver disease [11].
Given these considerations, the early diagnosis of CFLD is urgently needed, and patients
with an early stage liver disease are more likely to benefit from therapy with ursodeoxycholic
acid (UDCA) [12]. Although defined criteria for the diagnosis and management of cystic fibro-
sis-associated liver disease have been published recently, they might miss early stages of CFLD,
especially in the absence of significant fibrosis deposition within the liver [8]. As shown in pre-
vious reports from our group and others, the measurement of liver stiffness with transient elas-
tography has a high diagnostic accuracy for the detection of CFLD in adults and children [4–
Table 1. Demographic and clinical data of the pediatric cystic fibrosis patient cohort.
Demographic and clinical data TEcon TEinc
Male (n/%) 18/66.7% 8/88.9%
Female (n/%) 9/33.3% 1/11.1%
Examination initial last initial last
Age (years) 10.0 (11) ±4.8 14.7 (16) ±4.7 10 (10) ±3.9 14.9 (14) ±4.0
Range 2–17 7–22 4–17 9–22
BMI (kg/m2) 16.7 (16.5) ±2.7 19.0 (18.1) ±3.4 15.9 (16.3) ±1.4 18.3 (18.9) ±1.8
Liver Stiffness (kPa) 4.66 (4.5) ±0.85 4.5 (4.3) ±0.74 4.4 (4.3) ±0.55 8.64 (8.2) ±1.71
Range 3.3–6.3 3.2–5.8 3.8–5.4 6.8–12.2
ALT (U/l) 25.1 (21) ±15.7 34.3 (26) ±27.5 44.3 (22) ±58.4 59.8 (32) ±65.2
Range 10–88 11–144 11–208 22–240
AST (U/l) 26.0 (25) ±7.1 37.0 (25) ±55.4 38.3 (29) ±19.8 57.9 (33) ±68.2
Range 15–46 14–316 20–84 23–248
APRI 0.19 (0.18) ±0.09 0.3 (0.2) ±0.39 0.31 (0.22) ±0.19 0.46 (0.28) ±0.45
Range 0.09–0.52 0.1–2.23 0.12–0.73 0.18–1.71
FIB-4 0.16 (0.15) ±0.08 0.28 (0.25) ±0.26 0.2 (0.17) ±0.08 0.32 (0.3) ±0.11
Range 0.03–0.34 0.1–1.56 0.07–0.34 0.19–0.62
Platelet count (G/l) 352 (333) ±99 301 (294) ±53 333 (329) ±48 297 (300) ±53
Range 220–757 217–405 245–406 201–363
AP(U/l) 254 (248) ±64 209 (184) ±119 260 (251) ±56 264 (279) ±76
Range 122–394 0.1–517 162–346 141–344
Bilirubin 0.43 (0.3) ±0.27 0.42 (0.5) ±0.17 0.33 (0.3) ±0.12 0.43 (0.5) ±0.09
Range 0.1–1 0.1–0.6 0.2–0.6 0.3–0.5
Albumin (g/dl) 45.3 (45.5) ±1.8 45.0 (46) ±2.8 42.1 (41) ±2.4 44.1 (44.2) ±2.6
Range 42–48 38–50 39–47 39–48
PTT (%) 34.8 (33.5) ±4.3 34.8 (34) ±2.9 34 (34) ±2.7 33 (3) ±1.6
Range 29–44 31–39 29–39 31–35
γ-GT (U/l) 11.5 (12) ±4.8 15.1 (13) ±8.3 16.1 (19) ±13.4 48.6 (25) ±71.3
Range 5–26 5–40 8–53 8–248
Ferritin (µg/l) 24.7 (21.5) ±10.6 35.1 (32) ±18.7 29.4 (24) ±9.9 37.8 (33) ±21.8
Range 11–50 6–98 17–45 6–70
Mean (median) ± SD and range is depicted, Abbreviations: SD = standard deviation; BMI = body- mass- index; TE = transient elastography; TEinc = group of
children with increasing liver stiffness, TEcon = control group of children without increasing liver stiffness; ALT = alanin- aminotransferase; AST = aspartate-
aminotransferase; APRI = Aspartate Aminotransferase to Platelet Ratio Index; FIB-4 = Fibrosis-4 index; AP = alkaline phosphatase; PTT = partial
thromboplastin time; γ-GT = γ–glutamyltransferase
https://doi.org/10.1371/journal.pone.0178784.t001
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6,12–14]. Thus, the approach of assessing of liver stiffness using TE sensitively and noninva-
sively, which directly reflects increased matrix deposition and fibrogenesis in the liver, can
complement or even facilitate conventional clinically oriented diagnosis by enhancing specific-
ity and improving early detection of CFLD.
Nevertheless, so far only two studies presented follow-up data for TE-assessment in CFLD
patients [4,12]. Karlas et al. described a stable course of CFLD in adult CF patients once they
have passed adolescence [4]. Van Biervliet et al. retrospectively showed stable liver stiffness in
Fig 2. The increase in liver stiffness (ΔTE) defines the development of CFLD in pediatric patients. (A) The receiver operating characteristics
(ROC) analysis identified a consistent increase of liver stiffness in 9 of 10 pediatric patients with a TE(4–5) >6.3 kPa and fixed the cut-off as rationale for
grouping ΔTEcut-off = 0.38 kPa/year. The frequency of CFLD (B), the enhancement of liver stiffness ΔTE (C), and the median stiffness (D) was increased
in the TEinc-group compared to the TEcon-group.
https://doi.org/10.1371/journal.pone.0178784.g002
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young CF patients without liver disease on the one hand, and progressively increasing stiffness
in young CF patients with developing liver disease on the other hand [12]. Our current work is
the first study to present prospective data showing that TE is a sensitive diagnostic tool for the
identification of patients at risk for progressing CFLD. In this regard, we calculated a cut-off
for the rise in liver stiffness of0.38kPa/year to be optimal for the identification of children
with progressively increasing liver stiffness.
8 out of 9 children of the TEinc-group were also identified to have CFLD ofy comprehensive
conventional criteria [8]. Nevertheless, these criteria failed in one patient of the TEinc group.
Fig 3. The longitudinal assessment of TE, APRI-score, and FIB-4-score indicated increased liver stiffness and fibrosis. (A) TE was enhanced in
the TEinc-group 4 and 5 years after the first assessment. (B) Although the ANOVA calculated p-value was rather low in comparison of TEinc and TEcon
4–5 years after the first examination, statistical significance was not reached. (C) FIB-4 was enhanced in patients of the TEinc-group 4 years after the first
examination, however it did not reach statistical significance at the 5th exploration. Interestingly, the FIB-4-score tends to increase gradually in patients of
the TEcon-group.
https://doi.org/10.1371/journal.pone.0178784.g003
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According to previously published data [4], no increase in liver stiffness was observed in adults
which underlines the hypothesis of a stable course of CFLD in the majority of adult CF patients
once they have passed adolescence [15].
A recently published, liver biopsy based study showed that the biomarker scores APRI and
FIB-4 differentiate between CFLD and CFnoLD in pediatric CFLD patients [2]. Therefore
APRI appears superior to FIB-4 and furthermore exhibited a high accuracy in predicting
severe liver fibrosis [2]. The positive correlation of APRI and FIB-4 with liver stiffness under-
lines that transient elastography performs diagnosing liver fibrosis in patients with CFLD.
A possible limitation of our study might be the lack of histopathologic assessment of CFLD
in our cohort. However, due to the focal nature of CFLD, liver biopsy is controversially dis-
cussed in CFLD and thus not acting as regular diagnostic [8,16]. Moreover, it would have been
desirable to include a higher number of patients in the pediatric cohort. Approximately 67% of
patients with cystic fibrosis develop hepatic steatosis, but the pathogenic and histomorphologic
relation of CFLD to NAFLD has not been investigated so far and the mechanism is not clearly
understood [17,18]. It has been suggested that the high risk of CF patients to develop CF
related diabetes is a prerequisite for hepatic steatosis [18]. Nevertheless, the different pheno-
types of CFLD may not be uniformly detected by TE and could not be distinguished in the cur-
rent study.
Conclusion
This study can be distinguished from other studies, as it is a prospective long term observation
of CF patients to be at risk for CFLD. Furthermore we compared TE with established histology
proven fibrosis scores (APRI and FIB-4). Our newly described cut-off for pathologic increase
of liver stiffness might enable to detect developing CFLD using consequent follow up TE mea-
surements before reaching the level of stiffness indicating established CFLD. With respect to
the limited size of the analyzed cohort, we perceive our study as a signal to encourage a pro-
spective, multi-center, long term follow up study to confirm our data and to refine the sug-
gested cut-off for the rise in liver stiffness for the identification of children at risk for
development of CFLD.
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